Web Research
Web Research — What the Internet Knows
The Bottom Line from the Web
The web tells a story the financials alone cannot: Molina's 2025 guidance collapse triggered a multi-firm securities class action, a Texas Medicaid fraud settlement, an S&P negative outlook, an S&P 500 demotion, and a Medicare Advantage Part D strategic exit — all within twelve months. The biggest incremental disclosures are (a) the Hindlemann v. Molina securities suit covering the Feb 5 – Jul 23, 2025 class period (with 10+ law firms competing for lead plaintiff and a derivative investigation opened April 2026), and (b) management's 2029 adjusted EPS target of $25 against a 2026 floor of just $5 — a five-fold ambition during active litigation. The Q1 2026 beat and BofA's "rare double-upgrade" to Buy at $250 indicate that the margin trough may be in, but credit covenant relief through Q3 2027 and a $3.3M CLO insider sale on May 11, 2026 cut against the cyclical-recovery narrative.
Consensus PT (low–high)
2026 EPS Floor
2029 EPS Target
What Matters Most
1. Securities class action over Feb–Jul 2025 disclosures — multi-firm pile-on
Hindlemann v. Molina Healthcare (No. 25-cv-09461, C.D. Cal.) — Class period Feb 5–Jul 23, 2025; lead-plaintiff deadline Dec 2, 2025; 10+ law firms soliciting (Frank R. Cruz, Robbins Geller, Schall, Glancy Prongay & Murray, Rosen, Kessler Topaz, BFA, Levi & Korsinsky, Bronstein, Pomerantz). Allegations: undisclosed medical-cost-trend assumptions, "dislocation between premium rates and medical cost trend," and that 2025 guidance was substantially likely to be cut. April 3, 2026 — Kahn Swick & Foti opened a separate officer/director derivative investigation, raising D&O and potential clawback risk.
Source: prnewswire.com (Nov 21, 2025) · Robbins Geller (Oct 3, 2025) · Kahn Swick & Foti (Apr 3, 2026)
2. Q4 2025 reset shattered the FY25 thesis — adjusted EPS $11.03 vs initial $24.50
Molina cut FY25 guidance three times: July 7 ($21.50–22.50), July 23 (no less than $19.00), and Oct 22 (third cut). The Q4 2025 print (Feb 5, 2026) delivered an adjusted loss of $2.75/share vs $0.43 consensus; full-year adj. EPS landed at $11.03 (-55% vs initial guide). Consolidated MCR climbed to 91.7% from 89.1%; pre-tax margin compressed to 1.3% from 3.9%. The Feb 6 reaction wiped ~28% from the share price intraday.
Sources: Reuters Q3 reaction (Oct 23, 2025) · Reuters Feb 6, 2026
3. Texas Medicaid fraud — $40M settlement (paid)
Texas Attorney General Ken Paxton's office secured a $40M settlement from Molina Healthcare of Texas and parent over Medicaid STAR+PLUS assessment timing — originating from a qui tam whistleblower. The Q1 2026 financials absorb the cash impact. This sits alongside a 2024 Illinois SNFist False Claims settlement and Molina Florida's $257,111 HHS-OIG CMP, evidencing a pattern of Medicaid program-integrity exposure rather than a one-off.
Source: Texas Attorney General · Bloomberg Law (Illinois SNF)
4. Medicare Advantage Part D exit — $93M impairment, strategic narrowing
Management announced a 2027 exit from traditional Medicare Advantage Part D (MAPD) alongside Q4 2025 results; Q1 2026 booked a $93M non-cash intangible impairment tied to the Bright Health Medicare assets acquired Jan 2024. MAPD was approximately $1B premium / $1.00/share earnings drag. Remaining Medicare focus narrows to ~$5B dual-eligible (D-SNP/FIDE-SNP) book, with D-SNP county footprint up 23% in 2025. Framed as proactive — but the impairment confirms partial write-down of the Bright Health deal.
Source: TipRanks impairment · Modern Healthcare (Feb 6, 2026)
5. Q1 2026 beat — first inflection signal
Q1 2026 (Apr 22, 2026): adjusted EPS $2.35 vs $1.57 consensus; consolidated MCR 91.1%; 2026 guidance reaffirmed at "at least $5 EPS" / $42B premium revenue. CEO Zubretsky called 2026 the "Medicaid industry margin trough." Shares jumped ~14–17% intraday — and BofA issued a "rare double upgrade" to Buy with a $250 PT and a 2029 EPS projection of $30 (vs Street ~$17.32).
Source: Reuters (Apr 22, 2026) · Insider Monkey (BofA)
6. Credit-agreement covenant relief through Q3 2027 — lender view diverges from "trough" narrative
On Feb 4, 2026 Molina amended its credit agreement to step the minimum interest-coverage covenant from 3.00x to as low as 1.75x–2.75x through Q3 2027. Same month, S&P revised the outlook to Negative (BB rating affirmed) citing capital-adequacy deterioration; leverage was 48% at 9/30/2025. Nov 18, 2025: priced $850M of 6.500% senior notes due 2031 — a coupon meaningfully above peer levels. The lender-implied stress window runs ~24 months longer than management's "one-year trough."
7. S&P 500 demotion + ~58% six-month drawdown drove forced passive selling
By the Nov 21, 2025 Bernstein note, MOH was down ~58% over six months. Market cap fell to ~$7.3B in early Feb 2026 — below the $22.7B large-cap threshold — triggering demotion to the S&P SmallCap 600 on March 23, 2026 and Russell-index reshuffles. 52-week range: $121–$313. Some technical selling is now behind the stock.
Source: Investing.com (Nov 21, 2025) · FinancialContent (Mar 16, 2026)
8. Mixed insider signal — CFO/COO/EVP/CLO bought early-2026, then CLO sold $3.31M on May 11, 2026
Buying (Mar 9, 2026 per Yahoo): CFO Mark Keim, COO James Woys, an EVP, and Chief Legal Officer Jeff Barlow made "substantial" insider purchases during disclosure scrutiny. Selling: trailing-12-month net seller (sold 20.87k for ~$4.0M vs bought 10.80k for $1.7M); CLO executed a $3,314,983 sale on May 11, 2026, then a further 17,811-share open-market sale ~Jun 2, 2026. Insider ownership remains 1.4%.
Source: Yahoo Finance · Simply Wall St
9. Investor Day May 8, 2026 — $25 adj. EPS by 2029 (vs Street ~$17.32)
Management targeted 2029 revenue of $50–52B and adjusted EPS of $25 (Morningstar read; Reuters reported $28–30 high case), implying pretax margin expansion from <1% in 2026 to ~2.5%. Stock fell ~3% — JPM and Barclays said the print "fell short of investor expectations." Mizuho cited "increased confidence in embedded earnings >$11/share." BofA's bull case projects $30. Wide dispersion = high optionality, contested credibility.
Source: Reuters (May 8, 2026) · Morningstar
10. State Medicaid RFP engine still firing — Florida sole-source + Illinois HealthChoice
Nov 14, 2025: Florida awarded MOH a sole-source statewide Medicaid Managed Care / CHIP contract (~120,000 members, ~$5–6B premium, Q4 2026 launch) — reversing prior loss. June 10, 2026: Illinois Department of Healthcare and Family Services awarded HealthChoice Illinois (effective Jan 1, 2027). Long-term RFP track record cited at 90% re-procurement and 80% new-contract win rates; ~$9B incremental annual premium contracted from 2025 RFPs + acquisitions.
Source: Stocktitan (Illinois)
11. Smart-money interest at the trough — Klarman/Baupost ~$84M position
Baupost (Seth Klarman) disclosed an $84.46M stake; Cobalt Capital opened a 115,000-share position (10.1% of 13F AUM, ~$22M) Nov 13, 2025; Redwood Capital added 51,600 shares Q4 2025. Multiple value managers stepping in at the cycle-trough — counterweight to bear thesis.
Source: Insider Monkey · Motley Fool Cobalt
12. Workforce reduction — California WARN notice Feb 11, 2026
A California WARN filing dated Feb 11, 2026 confirms a mass-layoff event (size not specified in the public source). Glassdoor analyst-role rating fell ~82% over 12 months; recent reviews reference "stressful" environment "due to recent layoffs and political environment." Operational stress consistent with the margin-pressure narrative.
Source: USA Today WARN tracker
Recent News Timeline
What the Specialists Asked
Governance and People Signals
Pattern: Officer-buying cluster in March 2026 during disclosure-scrutiny window was a tentatively bullish alignment signal, but the CLO's $3.31M sale on May 11, 2026 — concurrent with active securities litigation — materially dilutes that signal. Net insider activity remains a 12-month seller.
Key people facts:
- CEO Joseph Zubretsky — in role since 2017, contract extended Aug 2024 through end-2027 with PSU vesting tied to financial targets set pre-crisis; TDC ~$18.34M; ownership 0.72%. Tenure has spanned the 2017 family-ouster turnaround through the 2025 thesis-breaking guidance cuts.
- CFO Mark Keim — role expanded Sept 4, 2024 to lead Medicaid Health Plans + Marketplace; plausible internal succession candidate.
- Board Chair Dale Wolf (Independent, since 2017 turnaround); Vice Chair Ronna Romney.
- 2025 say-on-pay vote drew only ~40% support; 2026 proxy explicitly addresses remediation via "direct investor engagement." 2026 vote outcome not yet in research corpus.
- May 6, 2026 annual meeting: shareholders approved (i) bylaw amendment allowing 20%+ holders to call special meetings (mildly activist-friendly) and (ii) larger equity plan; ~90.55% of shares represented; 10 directors elected through 2027.
- ESOP shelf: 1.5M-share registration (~$264.3M) flagged June 2026 — potential dilution.
Officer/director derivative investigations: Kahn Swick & Foti (Apr 3, 2026) and Grabar Law (May 26, 2026) opened separate investigations of MOH officers and directors. Derivative exposure adds D&O coverage and potential clawback risk beyond the securities class action.
Industry Context
External evidence beyond the Industry primer that materially affects MOH's thesis:
1. The 2025 dislocation was sector-wide, but MOH's relative miss was sharper. UnitedHealth suspended FY25 guidance entirely; Centene and Elevance also cut. MOH's Q3 2025 ~50% EPS miss and 16.8% single-day drop were materially worse than peers — challenging the "best-in-class Medicaid margin cushion" narrative. (Yahoo Oct 2025)
2. 2027 MA rate finalized at +2.48% — a relative tailwind, but MOH is exiting MAPD anyway. CMS proposed only +0.09% in Jan 2026, sparking a sector-wide selloff. Finalization in April 2026 came at +2.48%. MOH stock benefited via correlation but the 2027 MAPD exit blunts direct upside; D-SNP focus retains policy-favorable positioning (CMS auto-enrollment rule).
3. Federal policy overhang — OBBBA work requirements begin Jan 1, 2027 across 40 states + DC. Industry-wide demand pressure on Medicaid expansion lives; MOH guidance does not yet include federal budget bill impacts. Mario Molina (former CEO) publicly called the cycle "just the beginning of a major downturn for insurers" (July 2025).
4. ACA enhanced subsidies expired end-2025. MOH is intentionally shrinking Marketplace ~50% in 2026 — peers similarly retrenching. Industry-wide Marketplace margin compression continues.
5. Smart-money flow contradicts retail/passive selling. While S&P 500 demotion drove forced passive selling, Klarman/Baupost, Cobalt, Redwood added on the drawdown — a divergence between systematic flow and concentrated value-investor positioning.